AstraZeneca (LON:AZN) Stock Rating Reaffirmed by Shore Capital

AstraZeneca (LON:AZNGet Rating)‘s stock had its “buy” rating reaffirmed by investment analysts at Shore Capital in a note issued to investors on Friday, reports.

AZN has been the topic of several other research reports. Berenberg Bank cut their price target on AstraZeneca from £120 ($141.01) to £118 ($138.66) and set a “buy” rating on the stock in a report on Wednesday, October 19th. UBS Group set a £101 ($118.68) target price on AstraZeneca in a research report on Thursday, November 10th. The Goldman Sachs Group set a GBX 6,950 ($81.67) price target on AstraZeneca in a report on Thursday, November 10th. JPMorgan Chase & Co. set a £125 ($146.89) price objective on AstraZeneca in a research note on Thursday, November 10th. Finally, Credit Suisse Group reaffirmed a “neutral” rating and set a £110 ($129.26) price target on shares of AstraZeneca in a research note on Friday, October 21st. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of £110.14 ($129.42).

AstraZeneca Price Performance

AstraZeneca stock opened at £109.20 ($128.32) on Friday. AstraZeneca has a 52 week low of GBX 8,090.32 ($95.07) and a 52 week high of £115.40 ($135.61). The stock has a fifty day moving average of £101.86 and a 200-day moving average of £104.83. The company has a debt-to-equity ratio of 88.97, a quick ratio of 0.59 and a current ratio of 0.81. The stock has a market capitalization of £169.21 billion and a P/E ratio of 10,018.35.

AstraZeneca Company Profile

(Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Recommended Stories

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.